检验医学与临床2023，Vol.20Issue(24)：3594-3598,5.DOI:10.3969/j.issn.1672-9455.2023.24.003
利妥昔单抗联合化疗治疗儿童成熟B细胞淋巴瘤的有效性和安全性的Meta分析
Meta-analysis of effectiveness and safety of rituximab combined chemotherapy for treating of childhood mature B-cell lymphoma
摘要
Abstract
Objective To systematically evaluate the efficacy and safety of rituximab combined chemother-apy in the treatment of childhood mature B-cell lymphoma.Methods The electronic databases such as PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure,and Wanfang Database were retrieved by computer.The two researchers respectively conducted the data extraction,quality evaluationand cross checking.The retrievaltime limit was from the establishment of the database to July 2022.The compara-tive studies of the rituximab combined chemotherapy andsimple rituximab were collected and the 3-year event free survival(EFS)and incidence rate of adverse reactions served as the outcome indicators.The STATA11.0 software was used for conducting the Meta-analysis,subgroup analysis,sensitivity analysis,and publication bi-as analysis.Results A total of 9 studies were included,including 908 patients with newly diagnosed pediatric mature B-cell lymphoma.The Meta-analysis results showed that,compared to the simple chemotherapy group,the 3-year EFS of the patients with newly diagnosed mature B-cell lymphoma in the rituximab combi-nation chemotherapy group was significantly increased(HR=0.37,95％CI:0.24-0.58,P＜0.05).Sub-group analysis showed 3-year EFS in after ≥≥ 6 times of rituximab use the rituximab combination chemothera-py group was higher than that in the simple chemotherapy group(HR=0.32,95％CI:0.17-0.57,P＜0.05),and there was no statistically significant difference in 3-year EFS between the rituximab combined chemotherapy group and the simple chemotherapy group in the rituximab four times(HR=0.41,95％CI:0.17-1.01,P＞0.05).There was no statistically significant difference in the incidence rate of≥4 grade ad-verse reactions between the rituximab combined chemotherapy group and the simple chemotherapy group(OR=1.24,95％CI:0.80-1.94,P＞0.05),the incidence rate of ≥3 grade neutropenia between the two groups was not statistically significant(OR=1.34,95％CI:0.62-2.91,P＞0.05),and the incidence rate of ≥3 grade infection between the two groups was statistically significant(OR=1.82,95％CI:1.23-2.71,P＜0.05).Conclusion Rituximab combined chemotherapy can improve the survival rate in children patients with mature B-cell lymphoma,and the application of ≥6 times of rituximab has better clinical effect with low-er overall incidence rate of adverse events.关键词
儿童/成熟B细胞淋巴瘤/利妥昔单抗/不良反应/无事件生存率Key words
children/mature B-cell lymphoma/rituximab/adverse effects/event-free survival分类
医药卫生引用本文复制引用
张明乐,刁玉巧,朱秀丽,郑钰,陈健,江莲,陈彦,戴若恒,闫祎炜..利妥昔单抗联合化疗治疗儿童成熟B细胞淋巴瘤的有效性和安全性的Meta分析[J].检验医学与临床,2023,20(24):3594-3598,5.基金项目
河北省重点研发计划项目(20377794D). （20377794D）
